key: cord-0977275-lrsoor3h authors: Kline, Adam; Trinh, Lily N.; Hussein, Mohammad H.; Elshazli, Rami M.; Toraih, Eman A.; Duchesne, Juan; Fawzy, Manal S.; Kandil, Emad title: Annual flu shot: Does it help patients with COVID‐19? date: 2021-09-27 journal: Int J Clin Pract DOI: 10.1111/ijcp.14901 sha: 3588e4728ba54de2fcc831a2812ba2d6e7122ad2 doc_id: 977275 cord_uid: lrsoor3h AIM OF THE STUDY: The impact of annual flu vaccination on the patients’ clinical course with COVID‐19 and the outcome were tested. METHODS: A total of 149 patients with COVID‐19‐positive admitted from March 20 to May 10, 2020, were retrospectively enrolled. RESULTS: Ninety‐eight (65.8%) patients received at least a single annual flu shot in the last year, and fifty‐one (34.2%) were never vaccinated. On presentation, vaccinated patients were more likely to present with gastrointestinal symptoms (P < .05). There were no significant differences between study groups in laboratory findings or clinical outcomes. In multivariate analysis, receiving the annual shot did not influence risk of intensive care unit admission (OR = 1.17, 95%CI = 0.50‐2.72, P = .72), intubation (OR = 1.40, 95%CI = 0.60‐3.23, P = .43), complications (OR = 1.08, 95%CI = 0.52‐2.26, P = .83) or mortality (OR = 1.29, 95%CI = 0.31‐5.29, P = .73). CONCLUSION: Although the benefits of the influenza vaccine for preventing disease and reducing morbidity in influenza patients are well established, no differences in outcomes for hospitalised patients with COVID‐19 who received their annual influenza vaccination versus the non‐vaccinated cohort were evident. There is a need for future meta‐analyses, including randomised controlled studies in which the number of cases is increased to validate these findings. Previous research has suggested an association between receiving the flu vaccine and an increased rate of contracting non-influenza viral respiratory illnesses (NIRVs) such as rhinoviruses, adenoviruses and coronaviruses. 6, 7 A proposed mechanism is virus interference, meaning that a natural influenza infection will provide temporary, non-specific immunologic resistance to NIRVs. Cowling et al found an increased risk of contracting a serologically confirmed NIRV in children who had received the trivalent influenza vaccine. 8 Nevertheless, other research demonstrated no relationship between being vaccinated and increased NIRVs. [9] [10] [11] A large study of military personnel in the United States demonstrated mixed results, concluding that influenza vaccination status did not increase a person's overall risk of an NIRV. However, in that study, vaccinated patients had an overall increased rate of coronavirus infections. 12 Common NIRVs have historically not been associated with severe morbidity or hospitalisations. Therefore, there are limited data on the effects of influenza vaccination and disease course in these patients. Although the influenza vaccine demonstrates benefit in patients hospitalised with acute respiratory illness caused by influenza, the impact on patients with COVID-19 is not known. 13 The purpose of this study is to evaluate the impact of annual influenza vaccination on the disease course and outcomes of COVID-19 in a cohort of patients with COVID- 19- A comparison between the vaccinated and unvaccinated patients was performed. The primary outcome was in-hospital mortality. Secondary outcomes were symptoms on initial presentation, ICU admission, need for mechanical ventilation and length of hospital stay. Prolonged intubation was defined when taking >2 days, and prolonged hospital stay was defined when staying in hospital >7 days. Clinical diagnosis of complications was made using standard definitions such as the Risk, Injury, Failure, Loss of Kidney Function, and End-stage kidney disease (RIFLE) score for renal injury. Berlin criteria were also used to identify patients with acute respiratory distress syndrome (ARDS). Data management was performed using SAS v9.4, while SPSS v26.0 was used for statistical analysis. χ 2 and Fisher's exact tests were applied for categorical variables. Student's t-test and Mann-Whitney U-test were applied for parametric and non-parametric continuous variables, respectively, according to data distribution checked by the Shapiro-Wilk test. The two-sided P-value was set to be significant at <.05. Using the G*Power tool (version 3.1.9.2.) at the specified sample size for each study group, the medium effect size = 0.5, and alpha error probability = 0.05, the estimated study power was 82%. Multiple regression analysis was iterated using binary logistic regression models for all outcomes and cox hazard proportionate regression model for survival, adjusted by age, sex, obesity and neuropsychiatric comorbidity. This study included 149 patients with COVID-19-positive, 98 (65.8%) received at least a single annual flu shot in the last year, and 51 (34.2%) were never vaccinated against the annual flu. Table 1 summarises the demographics and clinical characteristics of patients with COVID-19 at admission. Of note, patients' mean age, body mass index (BMI), and comorbid conditions were similar between groups. There were more women in the vaccinated group (66, 67.3%) compared with the unvaccinated group (21, 41.2%) (P = .003). On presentation, vaccinated patients were more likely to present with gastrointestinal symptoms such as nausea, vomiting and diarrhoea (P = .028). The most common chief complaint was shortness of breath, which occurred in 30 (58.8%) of unvaccinated patients and 55 (56.1%) in vaccinated patients. On clinical assessment, there were no differences between groups in terms of vital signs or severity of COVID-19 disease (all vital sign P-values > .05). Table 2 summarises the laboratory findings between groups on admission. There were no significant differences in arterial blood glass, complete blood count, complete metabolic panel, and glycaemic profile between vaccinated and unvaccinated COVID-19 patients. Binary logistic regression analysis was performed, which adjusted data by age, gender and body mass index (Figure 1) . These results demonstrated no significant differences between vaccinated and unvaccinated patients in ICU admission, intubation, complications (AKI, ARDS, sepsis), prolonged intubation (greater than or equal to 2 days), prolonged hospital stay (greater than or equal to 7 days) or mortality. The patients' disease course. [13] [14] [15] [16] Our study had a few limitations. Firstly, our study population was limited to one geographic area in the South-eastern United States, with data from two hospitals. Secondly, because of the retrospective nature of this study, information about patients' influenza vaccination status for the 2019-2020 season was limited because of the differing electronic medical records used. As well, there was no information gathered on the type of influenza vaccine received. We hypothesised that patients who received the influenza vaccine might have a more favourable immune response to COVID-19. there is a need for future metanalyses, including randomised controlled studies in which the number of cases is increased to validate the study findings. The benefits of the influenza vaccine for preventing disease spread and reducing morbidity in influenza patients are well established. However, our study showed no differences in key outcomes for hospitalised patients with COVID-19 who received their annual influenza vaccination. The 2020-2021 influenza vaccine is recommended for all individuals without a contraindication and should be prospectively studied in large-scale, multicentre studies to evaluate any impact on the overall COVID-19 disease burden. The authors declare no conflict of interest. All datasets presented in this study are included in the article. Binary logistic regression analysis of annual flu shot on COVID-19 outcomes adjusted by age, sex and body mass index. OR (95% CI): Odds ratio (95% confidence interval) Meta-analysis on serial intervals and reproductive rates for SARS-CoV-2 Time-varying reproductive rates for SARS-CoV-2 and its implications as a means of disease surveillance on lockdown restrictions Covid-19 in critically ill patients in the Seattle region-case series The Flu Season History and evolution of influenza control through vaccination: from the first monovalent vaccine to universal vaccines Potential effect of virus interference on influenza vaccine effectiveness estimates in test-negative designs Assessment of temporally-related acute respiratory illness following influenza vaccination. Vaccine Increased risk of noninfluenza respiratory virus infections associated with receipt of inactivated influenza vaccine Influenza vaccination is not associated with detection of noninfluenza respiratory viruses in seasonal studies of influenza vaccine effectiveness Live attenuated influenza vaccine, trivalent, is safe in healthy children 18 months to 4 years, 5 to 9 years, and 10 to 18 years of age in a community-based, nonrandomized, open-label trial Influenza and other respiratory virus infections in outpatients with medically attended acute respiratory infection during the 2011-12 influenza season. Influenza Other Respir Viruses Influenza vaccination and respiratory virus interference among Department of Defense personnel during the 2017-2018 influenza season Influenza vaccine effectiveness in preventing influenza-associated intensive care admissions and attenuating severe disease among adults in New Zealand Efficacy and effectiveness of live attenuated influenza vaccine in school-age children Effectiveness of MF59-adjuvanted seasonal influenza vaccine in the elderly: a systematic review and meta-analysis Influenza vaccine effectiveness to prevent influenza-related hospitalizations and serious outcomes in Canadian adults over the 2011/12 through 2013/14 influenza seasons: A pooled analysis from the Canadian Immunization Research Network (CIRN) Serious Outcomes Surveillance (SOS Network). Vaccine Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia -a systematic review, meta-analysis, and meta-regression Predicting mortality due to SARS-CoV-2: a mechanistic score relating obesity and diabetes to COVID-19 outcomes in Mexico Risk factors of critical & mortal COVID-19 cases: a systematic literature review and meta-analysis Annual flu shot: Does it help patients with COVID-19?